-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TLX-66 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TLX-66 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TLX-66 in Acute Lymphocytic Leukemia (ALL,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TLX-66 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TLX-66 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TLX-66 in Acute Myelocytic Leukemia (AML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TLX-66 in Juvenile Myelomonocytic Leukemia (JMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TLX-66 in Juvenile Myelomonocytic Leukemia (JMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TLX-66 in Juvenile Myelomonocytic Leukemia (JMML) Drug Details: TLX-66...
-
Product Insights
NewNet Present Value Model: Telix Pharmaceuticals Ltd’s TLX-101
Empower your strategies with our Net Present Value Model: Telix Pharmaceuticals Ltd's TLX-101 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tulmimetostat in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tulmimetostat in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tulmimetostat in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TLX-250 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TLX-250 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TLX-250 in Metastatic Renal Cell Carcinoma Drug Details: TLX-250...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Chronic Cough
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Chronic Cough report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Chronic Cough Drug Details: Acloproxalap (ADX-629) is under development...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...